NEW YORK (GenomeWeb) – Charles River Laboratories said this week it will license its collection of patient-derived xenograft (PDX) tumors to InSphero. In addition, Charles River will use InSphero's proprietary 3D cell culture technology to extend and complement its preclinical services, using in vitro InSight tumor Microtissues derived from its existing PDX collection.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.